MENLO PARK, Calif., Nov 19, 2009 (BUSINESS WIRE) -- Geron Corporation (GERN, Trade ) today announced the presentation of interim data from its ongoing trial of imetelstat (GRN163L), a telomerase inhibitor drug, in patients with refractory, advanced solid cancers at the 2009
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. This Phase I study of ...